Health
Regeneron Inks $3 Billion Fujifilm Deal to Bolster US Drugmaking
Regeneron is in the midst of a planned $3.6 billion expansion of its campus in Tarrytown, New York.
Photographer: Michael Nagle/BloombergThis article is for subscribers only.
Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to help manufacture its medicines in the US, as the threat of tariffs looms over the nation’s drug supply.
Fujifilm will produce drugs for Regeneron, maker of the $14 billion a year inflammation treatment Dupixent, at its facility in Holly Springs, North Carolina. The site is slated to begin operations later this year and future expansions are already being planned, Fujifilm said.